KOL Insight: Type 2 Diabetes Mellitus [2020]

Maximum Purchase:
1 unit
Publication Date:
August 2020
Licence Type:
Multi-user licence
Adding to cart… The item has been added

Therapy Trends KOL Insight: Type 2 Diabetes Mellitus

What are the prospects for emerging GLP-1 receptor agonists such as Eli Lilly's tirzepatide and Sanofi's efpeglenatide and how can they differentiate themselves in this crowded market? KOLs argue for earlier use of established GLP-1RA such as Eli Lilly's Trulicity and Novo Nordisk's Ozempic - why? And which SGLT-2i/GLP-1RA therapies are winning KOL support? US and European KOLs critically assess the prospects of launched and pipeline therapies.

Therapy Trends reports give you an edge by delivering actionable intelligence to help you make informed decisions about your product. Based entirely on in-depth interviews with the world's foremost KOLs, Therapy Trends research focuses on the major battlegrounds for market share and answers critical business questions about product positioning and competitiveness.
I want an edge. Let's talk

Key questions answered

  • Why do KOLs consider GLP-1RA/basal insulin fixed-dose combinations such as Sanofi's Soliqua and Novo Nordisk's Xultophy to be niche products?
  • Will the novel mechanism of Sanofi's SGLT1/2 dual inhibitor sotagliflozin be sufficient to compete with established competitors?
  • Why do KOLs believe Novo Nordisk's once-weekly injectable insulin icodec could be a transformative therapy?
  • In what settings do KOLs see pipeline products such as AMMTeK's glibenclamide and Poxel's imeglimin providing value?

Examples of Therapies Covered

Invokana Jardiance
Steglatro Synjardy
Tresiba Toujeo
Ryzodeg Lyumjev
Efpeglenatide Tirzepatide

Partial List of Participating KOLs

  • Prof. Jay S. Skyler, M.D., MACP. Professor of Medicine,
    University of Miami Leonard M. Miller School of Medicine, Miami, FL.
  • Prof. Joel Zonszein, MD, CDE, FACE, FACP.
    Director of the Diabetes Center Montefiore Medical Center and Albert Einstein College of Medicine, NY.
  • Prof. Osama Hamdy, MD, PhD, FACE. Medical Director/Clinical Investigator,
    Joslin Diabetes Center, Harvard Medical School, Boston, MA.
  • Dr Peter Winocour, MD, FRCP. Consultant Physician,
    Clinical Director, East and North Hertfordshire NHS Trust, Lister Hospital, Stevenage, UK.
  • Prof. Bernard Charbonnel, MD.
    Chemin de la Houssinière, University of Nantes, F-44300, Nantes, France.
  • Prof. Jens Juul Holst, MD.
    Director of the Research Cluster for Diabetes and Obesity and Vice Chairman, Faculty of Health Sciences, University of Copenhagen, Denmark
FirstWord PerspectivesWe engage the world's leading key opinion leaders, ensuring the viewpoints delivered are authoritative and consequential. Strict screening criteria ensures high-quality interviews.
FirstWord PerspectivesOur-in house senior analysts and medics leverage their disease area knowledge and market research expertise to identify the key questions and issues.
FirstWord PerspectivesOur reports provide a detailed analysis, based on the candid views of world-renowned KOLs, of how treatment algorithms are likely to evolve over the next 3-5 years.
Continuous Monitoring
Our analysts continually monitor the market and re-engage KOLs throughout the year, delivering event-driven KOL insights on the impact of market changing events such as new clinical trials, pivotal trial results, drug approvals, drug launches and safety alerts.
Boardroom Ready
Short on time? All reports are supported by a convenient slide pack summarising the core of the analysis, making it easy to share with key stakeholders.
Future Driven
Our reports cover the pipeline products that will shape the future, helping you uncover where threats and opportunites will emerge.
Deep Dive
Extensive KOL interviews result in hundreds of direct KOL quotes, providing you with an unbiased and comprehensive view of key market-shaping issues.
Contact Us
First Name*
Last Name*
Job Title*
Company Name *
Country Name *
Job Function
Account Owner